Gilead Sciences reports positive data from HIV therapy trial

Gilead Sciences has reported positive data from the Phase Ib clinical trial of lenacapavir, along with broadly neutralising antibodies (bNAbs) teropavimab and zinlirvimab, to treat HIV.